Talaria Prize Winner Emily J. Pomeroy: Innovator Mindset Is Key to Commercialization Success

Biotechne acquires B-MoGen, a start-up developed at the UMN by CGE Faculty Branden Moriarity, Beau Webber and David Largaespada.


CGE's Dan Voytas elected to National Academy of Sciences


CGE welcomes new members Paul Orchard and Daniel Schmidt! We look forward to hearing your research at upcoming meetings!


CGE's Scott McIvor publishes research In Molecular Therapy of preclinical study data from MPS II In Vivo Genome Editing Program
Press Release | Manuscript


CGE's Dan Voytas announces new Center for Precision Plant Genomics
Developing plant genomes-by-design, made possible by recent advances in gene editing and plant synthetic biology


CGE's Scott McIvor recognized in Star Tribune article
UofM research pivotal in landmark gene editing trial
The second, third and additional attempts may occur in Minneapolis as researchers race to prove the safety and effectiveness of editing genes inside patients.


Genome Engineering: Center Positions Minnesota as North Star of Genome - Genome Engineering News feature on CGE
At the University of Minnesota, the CGE's Research Expands from 'Sleeping Beauty' Transposon System - by Alex Philippidis


CGE's Reuben Harris named a 2017 Distinguished McKnight University Professor
Reuben Harris is dedicated to advancing frontiers in mutation research. He has made breakthrough discoveries on mechanisms of mutation in multiple areas including bacterial evolution, antibody diversification, retrovirus restriction, and cancer pathogenesis. His fundamental discoveries have become textbook models and informed strategies for improving human health. His recent work on cancer mutation has revealed a major pathogenic role for enzymes called APOBECs, and this breakthrough has created clear opportunities for diagnostic and therapeutic advances.


UMN startup ApoGen Biotech (founder CGE member Reuben Harris) receives $7mil to create drug for cancer treatment
ApoGen Biotechnologies is working on a method to block enzymes that induce mutations in tumors, allowing traditional treatments to be more effective. The startup just received $7 million and is planning to open a research facility in the next year.